About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

could break 40 today.. looks promissing, shares mag should do something on this

about to tick up again.. bleeding heck, it might just happen today

Notable milestones in 2004/5 include:

* flotation on AIM
* licensing of 4 cancer drug targets to OSI Pharmaceuticals, in a deal worth
up to $18.8M depending on results
* collaboration with structure-based drug discovery company Sareum plc, to
advance EiRx kinase targets to Phase I/II clinical trials
* acquisition of oncology company Auvation Ltd
* collaborative research agreement with Merck & Co. Inc. to evaluate EiRx's
siRNA delivery technology
* award of a Marie Curie Programme grant from the European Commission, to
support development of the company's screening, chemistry and efficacy
testing capabilities



Potential new therapies for colorectal and other cancers



A grant from the Marie Curie Programme helped fund the development of EiRx's
EnPAD(TM) technology, which has been designed to identify novel drug candidates
targeted against specific biological pathways. Using its EnPAD(TM) technology
together with its ALIBI(TM) platform, EiRx's scientists have discovered a series
of related compounds with selective activity against transformed cell types
including colorectal and breast cancer cell lines. The company has submitted
patent applications to protect these novel therapeutic candidates in key global
markets.

big volume today... news tomorrow ???

4 million buy just went through!

I believe we have news this week

should see large volumes again this afternoon

we have a big link with BIOFOCUS.. research this heavily.. you will see what i mean

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20061121005028&newsLang=en

Hematological Cancers Drug Pipeline Update 2006 Lists More Than ...
Business Wire (press release), CA - 10 minutes ago
... to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront. There are today ...

The only volume i can see is selling hence the share price drop.

Link is informative but have to agree with Marcel.

agree, positive news is what it needs ! :)

been told there is news tomorrow.. hold on tight

PH
potatohead - 09 Nov 2006 15:34 - 505 of 581
last chance... rumour of news tomorrow

driver, we may all be caught in a time warp ! :)

News tomorrow PH?!
kim

yes there must be, was told news very very soon.. put it this way, latest by friday.. otherwise the ceo has some explaining to do

has anyone got the impression that these 500k sells is someone trying to short the stock..

If there was 10 or 20 of them i might agree but not for just 2

MORE RAMPS THAN KWIK-FIT relax the news will come , i cannot see anyone shorting 500k = 1500 if they are must be desperate and funking i,am still in 5m

MGI Pharma to Present at the Lazard Capital Markets Third Annual Life Sciences Conference


MINNEAPOLIS--(BUSINESS WIRE)--Nov 20, 2006 - MGI PHARMA, INC. (Nasdaq:MOGN) today announced that Bill Spengler, Executive Vice President and Chief Financial Officer of MGI PHARMA, will present at the Lazard Capital Markets third annual Life Sciences Conference in New York City on Wednesday, November 29, 2006 at 10:00 a.m. Eastern Time. Mr. Spengler will provide an overview of the Company, its products, pipeline and 2007 corporate goals.


PIPELINE NEWS NEXT WEEK... this is what we have been waiting for